Live news related to ABIVAX stock (FR0012333284): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The French biotech faces a sharp setback the day after the phase 3 results of its flagship drug candidate in ulcerative colitis. The market heavily pe…
Abivax announced on Monday positive results from the phase 3 ABTECT maintenance trial evaluating obefazimod in active moderate to severe ulcerative co…
The French biotech continues its climb after several weeks of volatility around its quarterly earnings. The stock stands out again among the SBF 120 l…
The French biotech continues its upward trend during the session, following several days of turmoil around its quarterly earnings. The stock reached a…
The French biotech regains control during the session after several days of volatility below €118. The stock has crossed a closely monitored technical…
The French biotech experiences a turbulent session. After breaking through its technical resistance and setting a new intraday high, the stock returne…
Abivax confirms the sustained efficacy of its candidate obefazimod in ulcerative colitis with three-year data, showing 68% of patients in clinical rem…
The French biotech regains momentum during the session, as the Paris market trends upward. The stock is among the best performers of the SBF 120 at mi…
French biotech Abivax is up 2.11% at €99.15 in early afternoon trading, in a Paris market trending upwards. The SBF 120 is up 0.55% during the session…
French biotech Abivax has gained 2.35% to €97.85 by midday this Tuesday, May 19, 2026. The stock is performing in a well-oriented Parisian market, wit…
